



英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

The English translation is for reference purposes only.

In the event of any discrepancy between the Chinese original and the English translation,
the Chinese original shall prevail.

2022

第一季度报告

The First Quarter Report in 2022



甘李药业股份有限公司
GAN & LEE PHARMACEUTICALS.
股票代码：603087
STOCK CODE: 603087

目 录

Contents

重要内容提示 Important Content Notes	3
一、主要财务数据 I Major Financial Data	4
二、股东信息 II Shareholder Information	9
三、其他提醒事项 III Other Reminders	14
四、季度财务报表 IV Quarterly Financial Statements	16

重要提示

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人甘忠如、主管会计工作负责人孙程及会计机构负责人(会计主管人员)周丽保证季度报告中财务报表信息的真实、准确、完整。

第一季度财务报表是否经审计

是 否

Important Content Notes

The Board of Directors, the Supervisors, directors, supervisors and senior management of Gan & Lee Pharmaceuticals. ('the Company') hereby assure that the content set out in the quarterly report is true, accurate and complete, and free from any false record, misleading representation or material omission, and undertake all the joint and several legal responsibilities.

Gan Zhongru (legal representative), Sun Cheng (Chief Accountant) and Zhou Li (Head of Accounting Department) hereby certify that the financial report set out in the annual report is true, accurate and complete.

Whether the first quarter financial statements are audited

Yes No

主要财务数据

Major Financial Data



一、主要财务数据

I Major Financial Data

(一) 主要会计数据和财务指标

(I) Major accounting data and financial indicators

单位：元 币种：人民币
Unit: RMB

项目	Item	本报告期 The reporting period	本报告期比上年同期增 减变动幅度(%) Changes in the reporting period over the same period of the previous year (%)	
营业收入	Operating revenue	689,990,891.63	25.77	
归属于上市公司股东的净利润	Net profits attributable to shareholders of the Company	113,297,551.23	-40.39	
归属于上市公司股东的扣除非经常性损益的净利润	Net profits attributable to shareholders of the Company after deduction of non-recurring profits or losses	159,093,760.57	47.57	
经营活动产生的现金流量净额	Net cash flow from operating activities	233,080,060.12	11.22	
基本每股收益(元/股)	Basic earnings per share (yuan / share)	0.20	-41.18	
稀释每股收益(元/股)	Diluted earnings per share (yuan/share)	0.20	-41.18	
加权平均净资产收益率(%)	Weighted average return on net assets (%)	1.11	减少0.99个百分点 Decreased by 0.99 percentage points	
		本报告期末 At the end of the reporting period	上年度末 At the end of the prior year	本报告期末比上年度末 增减变动幅度(%) Changes at the end of the reporting period from the end of the prior year (%)
总资产	Total assets	10,917,097,239.93	10,853,163,478.10	0.59
归属于上市公司股东的所有者权益	Owners' equity attributable to shareholders of the listed company	10,285,542,701.36	10,167,304,894.99	1.16

注：“本报告期”指本季度初至本季度末3个月期间，下同。

Note: "This reporting period" refers to the three-month period from the beginning of the quarter to the end of the quarter, the same below.

(二) 非经常性损益项目和金额

(II) Items and amounts of non-recurring profit or loss

单位：元 币种：人民币
Unit: RMB

项目	Items	本期金额 Amount for the reporting period
计入当期损益的政府补助，但与公司正常经营业务密切相关，符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外	Government grants recognized in profit or loss other than grants which are closely related to the company's business and are either in fixed amounts or determined under quantitative methods in accordance with the national standard	4,675,858.61
除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债产生的公允价值变动损益，以及处置交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债和其他债权投资取得的投资收益	Profit or loss on changes in the fair value of financial assets held for trading, derivative financial assets, held for trading financial liabilities and derivative financial liabilities and investment income on disposal of financial assets held for trading, derivative financial assets, held for trading financial liabilities, derivative financial liabilities and other debt investments, other than those used in the effective hedging activities relating to normal operating business	-59,122,598.66
除上述各项之外的其他营业外收入和支出	Other non-operating revenue or expenses than the above items	33,637.07
其他符合非经常性损益定义的损益项目	Other losses and profits conforming to the definition of non-recurring profit and loss	584,528.40
减：所得税影响额	Less: Amount affected by income tax	-8,032,365.24
合计	Total	-45,796,209.34

将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益项目的情况说明

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies Offering Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

适用 不适用

Applicable Not Applicable

(三) 主要会计数据、财务指标发生变动的情况、原因 (III) Changes and reasons in major accounting data and financial indicators

√适用 □不适用

√Applicable □ Not Applicable

项目名称	Items	变动比例 (%) Change ratio (%)	主要原因	Main reason
归属于上市公司股东的净利润	Net profits attributable to shareholders of the Company	-40.39	本报告期公司实现营业收入6.90亿元，同比增长25.77%，主要系公司制剂类胰岛素产品销售增长所致；而实现归属于上市公司股东的净利润1.13亿元，同比下降40.39%，主要系公司持有的证券投资公允价值变动损失、销售费用同期增加所致。	During the reporting period, the company achieved an operating income of RMB 690 million, a year-on-year increase of 25.77%, mainly due to the increase in sales of the company's prepared insulin products; while the net profit attributable to shareholders of the Company was RMB 113 million, a year-on-year decrease of 40.39%, mainly due to the company's It was due to the loss from changes in fair value of securities investments held and the increase in sales expenses over the same period.
归属于上市公司股东的扣除非经常性损益的净利润	Net profits attributable to shareholders of the Company after deduction of non-recurring profits or losses	47.57	本报告期归属于上市公司股东的扣除非经常性损益的净利润同比增长47.57%，主要系本报告期营业收入所致。	The net profit attributable to shareholders of the Company after deducting non-recurring profit or loss during the reporting period increased by 47.57% year-on-year, mainly due to the increase in operating income during the reporting period.
基本每股收益(元/股)	Basic earnings per share (yuan/ share)	-41.18	主要系本报告期归属于上市公司股东的净利润同比下降所致。	Mainly due to the year-on-year decrease in net profit attributable to shareholders of Company during the reporting period.
稀释每股收益(元/股)	Diluted earnings per share (yuan / share)	-41.18	同上。	Ditto.
应交税费	Taxes payable	-53.02	主要系本报告期应交所得税减少所致。	Mainly due to the decrease in income tax payable during the reporting period.
销售费用	Selling expenses	50.42	主要系本报告期市场推广及咨询费、职工薪酬增加所致。	This was mainly due to the increase in marketing and consulting fees and employee salaries during the reporting period.
财务费用	Financial expenses	-484.07	主要系本报告期利息收入增加所致。	Mainly due to the increase in interest income during the reporting period.

投资收益	Investment income/ (loss)	-48.92 主要系本报告期大额存单收益较上年同期减少所致。	Mainly due to the decrease in the income form large certificates of deposits during the reporting period compared with the same period of last year.
公允价值变动收益	Gain/(loss) on the changes in fair value	-181.29 主要系证券投资公允价值波动所致。	Mainly due to fluctuations in the fair value of securities investments.
信用减值损失	Credit impairment losses	不适用 主要系本报告期转回应收账款坏账准备所致。	It was mainly due to the transfer of bad debt provision for accounts receivable during the reporting period.
营业外支出	Non-operating expenses	-94.26 主要系本报告期固定资产报废损失减少所致。	Mainly due to the decrease in the loss from the scrapping of fixed assets during the reporting period.
所得税费用	Income tax expense	-50.57 主要系本报告期归属于上市公司股东的净利润减少所致。	It was mainly due to the decrease in net profit attributable to shareholders of Company during the reporting period.

股东信息

Shareholder Information



二、股东信息

II Shareholder Information

(一) 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表

(I) The total number of ordinary shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders

单位：股
Unit: Share

报告期末普通股股东总数		报告期末表决权恢复的优先股股东总数(如有)		质押、标记或冻结情况		
Total number of ordinary shareholders at the end of the reporting period		Total number of preferred shareholders with voting rights restored at the end of the reporting period (if any)		Status of shares pledged, tagged or frozen		
84,479		None		None		
前十名股东持股情况						
The shareholding of top ten shareholders						
股东名称(全称)	Shareholder name (full name)	股东性质	持股数量	持股比例(%)	持有有限售条件股份数量	股份状态
		Nature of shareholders	Number of shares held	Shareholding ratio (%)	Number of restricted shares held	If pledged or frozen
甘忠如	Gan Zhongru	境内自然人	177,135,207	31.54	177,135,207	无
		Natural persons in China				None
明华创新技术投资(香港)有限公司	MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED	境外法人	77,013,100	13.71	15,875,800	无
		Overseas corporation				None
北京旭特宏达科技有限公司	Beijing Xute Hongda Technology Co., Ltd.	境内非国有法人	47,494,437	8.46	47,494,437	无
		Non-state-owned corporation in China				None
Vast Wintersweet Limited	Vast Wintersweet Limited	境外法人	34,056,996	6.06	5,777,913	无
		Overseas corporation				None
STRONG LINK INTERNATIONAL LIMITED	STRONG LINK INTERNATIONAL LIMITED	国有法人	25,168,737	4.48	4,256,033	无
		State-owned corporation in China				None
GS Direct,L.L.C.	GS Direct,L.L.C.	境外法人	17,670,544	3.15	3,937,644	无
		Overseas corporation				None
北京宽街博华投资中心(有限合伙)	Beijing Kuanjie Bohua Investment Center (L.P)	其他	8,397,341	1.50	2,781,922	无
		Other				None
甘喜茹	Gan Xiru	境内自然人	6,223,276	1.11	6,223,276	无
		Natural persons in China				None
香港中央结算有限公司	Hong Kong Securities Clearing Company Limited	境外法人	5,381,503	0.96	0	无
		Overseas corporation				None
Hillhouse G&L Holdings (HK) Limited	Hillhouse G&L Holdings (HK) Limited	境外法人	4,357,832	0.78	4,357,832	无
		Overseas corporation				None

单位：股 Unit: Share	前十名无限售条件股东持股情况 The shareholding of top ten shareholders with trading limited conditions		股份种类及数量 Category and number of shares
	持有无限售条件流通股的数量 Number of Floating shares	种类 Category	数量 Number
股东名称 Shareholder name			
明华创新技术投资(香港)有限公司 MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED	61,137,300	人民币普通股 RMB ordinary shares	61,137,300
Vast Wintersweet Limited	28,279,083	人民币普通股 RMB ordinary shares	28,279,083
STRONG LINK INTERNATIONAL LIMITED	20,912,704	人民币普通股 RMB ordinary shares	20,912,704
GS Direct, L.L.C.	13,732,900	人民币普通股 RMB ordinary shares	13,732,900
北京宽街博华投资中心(有限合伙) Beijing Kuanjie Bohua Investment Center (L.P)	5,615,419	人民币普通股 RMB ordinary shares	5,615,419
香港中央结算有限公司 Hong Kong Securities Clearing Company Limited	5,381,503	人民币普通股 RMB ordinary shares	5,381,503
中国银行股份有限公司－招商国 证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	2,689,521	人民币普通股 RMB ordinary shares	2,689,521
甘一如 Gan Yiru	2,215,637	人民币普通股 RMB ordinary shares	2,215,637
马鞍山铸成长企业管理咨询合 伙企业(有限合伙) Maanshan Zhu Growth Enterprise Management Consulting Partnership (Limited Partnership)	1,144,547	人民币普通股 RMB ordinary shares	1,144,547
凌知喻 Ling Zhiyu	1,000,013	人民币普通股 RMB ordinary shares	1,000,013

公司控股股东、实际控制人甘忠如持有北京旭特宏达科技有限公司65.02%的股权；甘喜茹为甘忠如胞妹；GS Direct与北京宽街博华投资中心(有限合伙)的实际控制人均为 The Goldman Sachs Group, Inc (高盛集团)。除以上情况外，其他股东之间不存在关联关系或一致行动。

The Company's controlling shareholder and actual controller Gan Zhongru holds 65.02% of the shares of Beijing Xute Hongda Technology Co., Ltd.; Gan Xiru is Gan Zhongru's sister; the actual controllers of GS Direct and Beijing Kuanjie Bohua Investment Center (Limited Partnership) is The Goldman Sachs Group, Inc. Except for the above circumstances, there is no associated relationship or concerted action among other shareholders.

上述股东关联关系或一致行动的解释
Explanation of the related relationship or concerted action of the above shareholders

前10名股东及前10名无限售股东参与融资融券及转融通业务情况说明(如有)
Explanation on the participation of the top 10 shareholders and the top 10 unrestricted shareholders in margin financing and securities lending and refinancing business (if any)

无
None

其他提醒事项

Other Reminders



三、其他提醒事项

需提醒投资者关注的关于公司报告期经营情况的其他重要信息

适用 不适用

III Other Reminders

Other important information about the company's operating conditions during the reporting period that need to be reminded of investors

Applicable Not Applicable

季度财务报表

Quarterly Financial Statements



四、季度财务报表

IV Quarterly Financial Statements

(一) 审计意见类型

(I) Audit opinion type

□ 适用 √ 不适用

□ Applicable √ Not Applicable

(二) 财务报表

(II) Financial statements

合并资产负债表

Consolidated Statement of Financial Position

2022年3月31日
31 March 2022编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB, Unaudited

项目	Item	2022年3月31日 31 March 2022	2021年12月31日 31 December 2021
流动资产:	Current Assets:		
货币资金	Cash and Cash equivalents	3,390,760,842.24	3,305,707,725.80
交易性金融资产	Financial assets held for trading	1,556,254,776.98	1,624,183,495.26
应收账款	Accounts receivable	742,425,962.41	933,817,309.12
应收款项融资	Financing receivables	938,470.00	845,608.13
预付款项	Prepayments	56,632,879.74	62,115,672.31
其他应收款	Other receivables	7,241,605.00	6,487,728.39
存货	Inventories	732,290,118.04	651,329,199.56
一年内到期的非流动资产	Current portion of non-current assets	279,006,095.89	276,442,945.21
其他流动资产	Other current assets	9,064,811.47	9,513,506.37
流动资产合计	Total current assets	6,774,615,561.77	6,870,443,190.15
非流动资产:	Non-current Assets:		
债权投资	Debt investment	201,332,602.74	201,358,630.13
其他非流动金融资产	Other non-current financial assets	30,000,000.00	30,000,000.00
固定资产	Fixed assets	1,672,126,846.28	1,704,289,335.05
在建工程	Construction in progress	950,979,491.93	874,912,702.42
使用权资产	Right-of-use assets	15,021,131.12	16,168,455.72
无形资产	Intangible assets	289,660,563.30	295,989,757.60
开发支出	Development expenditures	623,721,705.75	576,495,277.97
长期待摊费用	Long-term prepaid expenses	11,936,974.01	12,377,643.77
递延所得税资产	Deferred tax assets	38,463,081.75	30,802,314.01
其他非流动资产	Other non-current assets	309,239,281.28	240,326,171.28
非流动资产合计	Total non-current assets	4,142,481,678.16	3,982,720,287.95
资产总计	Total assets	10,917,097,239.93	10,853,163,478.10

合并资产负债表 (续)

Consolidated Statement of Financial Position(Continued)

项目	Item	2022年3月31日 31 March 2022	2021年12月31日 31 December 2021
流动负债：	Current Liabilities		
应付账款	Accounts payable	33,796,782.70	37,740,865.36
预收款项	Receipts in advance		
合同负债	Contract liabilities	31,618,509.56	36,563,187.93
应付职工薪酬	Payroll and employee benefits payable	139,854,500.64	135,888,765.67
应交税费	Taxes payable	60,926,617.27	129,688,497.93
其他应付款	Other payables	141,125,093.85	137,580,423.10
一年内到期的非流动负债	Current portion of non-current liabilities	6,577,548.63	7,954,225.55
其他流动负债	Other current liabilities	144,565.11	115,137.93
流动负债合计	Total current liabilities	414,043,617.76	485,531,103.47
非流动负债：	Non-current Liabilities:		
租赁负债	Lease liabilities	13,043,875.89	12,166,086.58
长期应付款	Long-term payable	10,159,292.94	10,199,292.94
递延收益	Deferred income	167,313,067.63	141,977,135.69
递延所得税负债	Deferred tax liabilities	27,157,219.35	36,147,457.18
非流动负债合计	Total non-current liabilities	217,673,455.81	200,489,972.39
负债合计	Total liabilities	631,717,073.57	686,021,075.86
所有者权益(或股东权益)：	Owners (or Shareholders') Equity:		
实收资本(或股本)	Paid-in capital (or share capital)	561,540,000.00	561,540,000.00
资本公积	Capital reserve	2,481,414,741.32	2,476,158,119.34
其他综合收益	Other comprehensive income	-3,756,403.03	-3,440,036.19
盈余公积	Surplus reserve	291,531,843.96	291,531,843.96
未分配利润	Retained earnings	6,954,812,519.11	6,841,514,967.88
归属于母公司所有者权益(或股东权益)合计	Equity attributable to owners of the parent	10,285,542,701.36	10,167,304,894.99
少数股东权益	Non-controlling interests	-162,535.00	-162,492.75
所有者权益(或股东权益)合计	Total owners' (or shareholders') equity	10,285,380,166.36	10,167,142,402.24
负债和所有者权益(或股东权益)总计	Total Liabilities and Shareholders' Equity	10,917,097,239.93	10,853,163,478.10

公司负责人：
Person in charge of the
company:

甘忠如
Gan Zhongru

主管会计工作负责人：
Chief accountant:

孙程
Sun Cheng

会计机构负责人：
Head of accounting
department:

周丽
Zhou Li

合并利润表

Consolidated Income Statement

2022年1—3月
January-March 2022编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB, Unaudited

项目	Item	2022年第一季度 The first quarters in 2022	2021年第一季度 The first quarters in 2021
一、营业总收入	I. Total Revenue	689,990,891.63	548,603,958.12
其中:营业收入	Including: Operating revenue	689,990,891.63	548,603,958.12
二、营业总成本	II. Total Operating Costs	500,134,589.51	407,274,243.98
其中:营业成本	Including: Operating costs	60,353,311.34	54,800,774.44
税金及附加	Taxes and surcharges	5,967,119.29	5,254,232.02
销售费用	Selling expenses	288,064,449.59	191,504,733.01
管理费用	General and administrative expenses	70,735,565.35	62,587,273.99
研发费用	R&D expenses	97,888,052.81	87,171,594.82
财务费用	Financial expenses	-22,873,908.87	5,955,635.70
加:其他收益	Add: Other income	5,260,387.01	6,060,549.66
投资收益(损失以“—”号填列)	Investment income/(loss) (loss is indicated with “-”)	5,634,860.83	11,031,455.33
公允价值变动收益(损失以“—”号填列)	Gain/(loss) on the changes in fair value (loss is indicated with “-”)	-64,757,459.49	79,663,567.91
信用减值损失(损失以“—”号填列)	Credit impairment losses (loss is indicated with “-”)	825,510.79	-429,103.82
资产减值损失(损失以“—”号填列)	Assets impairment losses (loss is indicated with “-”)		
资产处置收益(损失以“—”号填列)	Gain/(loss) from disposal of assets (loss is indicated with “-”)		433,814.00
三、营业利润(亏损以“—”号填列)	III. Operating Profit (loss is indicated with “-”)	136,819,601.26	238,089,997.22
加:营业外收入	Add: Non-operating revenue	58,383.38	72,589.27
减:营业外支出	Less: Non-operating expenses	24,746.31	430,822.25
四、利润总额(亏损总额以“—”号填列)	IV. Profit Before Tax (loss is indicated with “-”)	136,853,238.33	237,731,764.24
减:所得税费用	Less: Income tax expense	23,555,729.35	47,654,373.71
五、净利润(净亏损以“—”号填列)	V. Net Profit (loss is indicated with “-”)	113,297,508.98	190,077,390.53
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“—”号填列)	1. Net profit from continuing operations (loss is indicated with “-”)	113,297,508.98	190,077,390.53

合并利润表 (续)

Consolidated Income Statement (Continued)

项目	Item	2022年第一季度 The first quarters in 2022	2021年第一季度 The first quarters in 2021
(二) 按所有权归属分类	(II) Categorized by ownership		
1. 归属于母公司股东的净利润 (净亏损以“-”号填列)	1. Net profit attributable to owners of the parent (loss is indicated with "-")	113,297,551.23	190,077,628.67
2. 少数股东损益(净亏损以“-”号填列)	2. Net profit attributable to non-controlling interests (loss is indicated with "-")	-42.25	-238.14
六、其他综合收益的税后净额	VI. Other Comprehensive Income, Net of Tax	-316,366.84	-327,563.03
(一) 归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, net of tax, attributable to owners of the parent	-316,366.84	-327,563.03
1. 不能重分类进损益的其他综合收益	1. Other comprehensive income will not be reclassified to profit or loss		
2. 将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified to profit or loss	-316,366.84	-327,563.03
(1) 外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	-316,366.84	-327,563.03
(二) 归属于少数股东的其他综合收益的税后净额	(II) Other comprehensive income, net of tax, attributable to non-controlling interests		
七、综合收益总额	VII. Total Comprehensive Income	112,981,142.14	189,749,827.50
(一) 归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent	112,981,184.39	189,750,065.64
(二) 归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests	-42.25	-238.14
八、每股收益：	VIII. Earnings Per Share:		
(一) 基本每股收益(元/股)	(I) Basic earnings per share (yuan/share)	0.20	0.34
(二) 稀释每股收益(元/股)	(II) Diluted earnings per share (yuan/share)	0.20	0.34

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

For business combination involving entities under common control occurred during the period, net profit of the acquiree generated before the business combination is nil, and net profit of the acquiree generated in prior period is nil.

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Person in charge of the company:	Gan Zhongru	Chief accountant:	Sun Cheng	Head of accounting department:	Zhou Li

合并现金流量表

Consolidated Statement of Cash Flows

2022年1—3月
January-March 2022编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB, Unaudited

项目	Item	2022年第一季度 The first quarters in 2022	2021年第一季度 The first quarters in 2021
一、经营活动产生的现金流量:	I. Cash Flows from Operating Activities:		
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	894,205,993.69	777,103,212.98
收到的税费返还	Tax refunds received	523,813.80	973,301.30
收到其他与经营活动有关的现金	Cash received relating to other operating activities	33,167,284.87	29,504,420.67
经营活动现金流入小计	Sub-total of cash inflows from operating activities	927,897,092.36	807,580,934.95
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	133,432,787.74	100,087,917.12
支付给职工及为职工支付的现金	Cash paid to and on behalf of employee	168,656,892.91	148,000,159.61
支付的各项税费	Cash paid for taxes	134,932,440.84	87,719,132.60
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	257,794,910.75	262,204,188.03
经营活动现金流出小计	Sub-total of cash outflows from operating activities	694,817,032.24	598,011,397.36
经营活动产生的现金流量净额	Net cash flow from operating activities	233,080,060.12	209,569,537.59
二、投资活动产生的现金流量:	II. Cash Flows from Investing Activities:		
收回投资收到的现金	Cash received from disposal of investments	880,000,000.00	630,000,000.00
取得投资收益收到的现金	Cash receipts from investment income	23,927,713.47	18,433,150.68
处置固定资产、无形资产和其他长期资产收回的现金净额	Net proceeds from disposal of fixed assets intangible assets and other long-term assets		562,389.38
收到其他与投资活动有关的现金	Cash received relating to other investing activities		
投资活动现金流入小计	Sub-total of cash inflows from investing activities	903,927,713.47	648,995,540.06
购建固定资产、无形资产和其他长期资产支付的现金	Purchase of fixed assets, intangible assets and other non-current assets	156,037,532.25	236,678,533.72
投资支付的现金	Cash paid for investments	1,080,000,000.00	580,000,000.00
支付其他与投资活动有关的现金	Cash paid relating to other investing activities	10,376,176.18	50,000,000.00
投资活动现金流出小计	Sub-total of cash outflows from investing activities	1,246,413,708.43	866,678,533.72
投资活动产生的现金流量净额	Net cash flow from investing activities	-342,485,994.96	-217,682,993.66

合并现金流量表 (续)

Consolidated Statement of Cash Flows (Continued)

项目	Item	2022年第一季度 The first quarters in 2022	2021年第一季度 The first quarters in 2021
三、筹资活动产生的现金流量：	III. Cash Flows from Financing Activities:		
吸收投资收到的现金	Cash received from investments		
筹资活动现金流入小计	Subtotal of cash inflows from financing activities		
分配股利、利润或偿付利息支付的现金	Cash payments for distribution of dividends or profit and interest expenses		
支付其他与筹资活动有关的现金	Cash payments relating to other financing activities	220,098.80	874,335.00
筹资活动现金流出小计	Sub-total of cash outflows from financing activities	220,098.80	874,335.00
筹资活动产生的现金流量净额	Net cash flow from financing activities	-220,098.80	-874,335.00
四、汇率变动对现金及现金等价物的影响	IV. Effect of Exchange Rate Changes on Cash and Cash Equivalents	-725,646.21	680,237.13
五、现金及现金等价物净增加额	V. Net Increase in Cash and Cash Equivalents	-110,351,679.85	-8,307,553.94
加：期初现金及现金等价物余额	Add: Cash and cash equivalents at beginning of year	639,768,344.07	291,335,227.78
六、期末现金及现金等价物余额	VI. Cash and Cash Equivalents at End of Year	529,416,664.22	283,027,673.84

公司负责人：
Person in charge of the
company:

甘忠如
Gan Zhongru

主管会计工作负责人：
Chief accountant:

孙程
Sun Cheng

会计机构负责人：
Head of accounting
department:

周丽
Zhou Li

2022年起首次执行新会计准则调整首次执行当年年初财务报表相关情况。

The first implementation of the new accounting standards from 2022 to adjust the financial statements at the beginning of the year for the first implementation.

适用 不适用

Applicable Not Applicable

特此公告

Special announcement.

甘李药业股份有限公司董事会
Gan & Lee Pharmaceuticals. Board of Directors

2022年4月26日
April 26, 2022



SCIENCE & EXCELLENCE

甘李药业有限公司

地址：北京市通州区潮县镇南凤西一路8号

网址：<http://www.ganlee.com>

电话：+86 010-80593699

邮编：101109